Evicenter
P&T meetings

Deramiocel (CAP-1002)

Duchenne muscular dystrophy

Launch
Not announced
Last updated
92 sources

Company-reported prevalence

Deramiocel

Overview

FieldValue
DrugDeramiocel (CAP-1002)
IndicationDuchenne muscular dystrophy
DiseaseDuchenne muscular dystrophy (DMD)
CompanyCapricor Therapeutics (developer, manufacturer, and Biologics License Application sponsor); Nippon Shinyaku Co., Ltd. and its US subsidiary NS Pharma, Inc. (exclusive distributor in the United States under a January 2022 agreement, which Capricor seeks to rescind through arbitration as of August 2026, and exclusive distributor in Japan under a February 2023 agreement); a binding term sheet with Nippon Shinyaku for the European region expired on April 1, 2026
Documents searchedCapricor Therapeutics website, Duchenne Muscular Dystrophy Overview and Pipeline pages (accessed October 2026); Capricor Therapeutics press releases, April 2023 to October 2026 (106 releases); Capricor Therapeutics Form 10-K for 2025 (filed March 17, 2026); Capricor Therapeutics Form 10-Q for the quarter ended June 30, 2026 (filed August 2026); Capricor Therapeutics corporate presentation, August 2026; Capricor Therapeutics and Parent Project Muscular Dystrophy webinar presentation, October 7, 2026; NS Pharma website, Duchenne, Pipeline and Products, and Newsroom pages (accessed October 2026); NS Pharma press releases naming deramiocel, March 6, 2025 and March 26, 2025; NS Pharma corporate brochure, September 2025; Nippon Shinyaku press releases naming CAP-1002, March 11, 2026, August 10, 2026, and August 25, 2026; Nippon Shinyaku Report 2025 (integrated report, part 1)
Data as ofOctober 14, 2026
Prepared byAI research agent (Claude); not yet reviewed by a person

Company statements of prevalence

United States

Number affected: Capricor Therapeutics website, October 2026

“it is estimated that approximately 15,000 boys and young men are living with the disease in the United States” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) website, Duchenne Muscular Dystrophy Overview, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Capricor Therapeutics Form 10-K for 2025, March 2026

“the patient population is approximately 15,000 individuals in the United States” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Capricor Therapeutics corporate presentation, August 2026

“15,000 DMD patients in United States” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) corporate presentation, August 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 26 of 38 (opens in a new tab)

Number affected: Capricor Therapeutics press release, October 2026

“DMD affects approximately 15,000 individuals in the United States and primarily impacts boys.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) press release, October 5, 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected: Capricor Therapeutics press release, June 2025

“the patient population is estimated to be approximately 15,000-20,000 in the United States.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2025) press release, June 11, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Europe

No evidence found.

Global

Number affected (worldwide): Capricor Therapeutics website, October 2026

“approximately 200,000 worldwide.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) website, Duchenne Muscular Dystrophy Overview, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected (worldwide): Capricor Therapeutics Form 10-K for 2025, March 2026

“approximately 200,000 worldwide.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Number affected (worldwide): Capricor Therapeutics corporate presentation, August 2026

“150,000-200,000 DMD patients worldwide” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) corporate presentation, August 2026, quoted passage highlighted (opens the full-size image in a new tab)
Captured from page 26 of 38 (opens in a new tab)

Number affected: Capricor Therapeutics press release, December 2023

“DMD afflicts approximately 200,000 boys and young men around the world.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2023) press release, December 11, 2023, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Other countries and regions

No evidence found.

Geography not stated

Birth prevalence: Capricor Therapeutics website, October 2026

“DMD occurs in approximately 1 in every 3,500 male births” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) website, Duchenne Muscular Dystrophy Overview, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Birth prevalence: Capricor Therapeutics Form 10-K for 2025, March 2026

“It is estimated that DMD occurs in approximately one in every 3,500 to 5,000 live male births” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2026) Form 10-K for 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Birth prevalence: Capricor Therapeutics press release, June 2025

“It is estimated that DMD occurs in approximately one in every 3,500 male births” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

Capricor Therapeutics (2025) press release, June 11, 2025, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Birth prevalence: NS Pharma website, August 2026

“Duchenne muscular dystrophy affects mostly males and occurs in an estimated one in 3,600 to 9,300 newborn babies.” (opens the source at this quote in a new tab)

Cited source: None stated in the document.

NS Pharma (2026) website, Duchenne, quoted passage highlighted (opens the full-size image in a new tab)
Captured from the passage on the page (opens in a new tab)

Sources the company cites

No evidence found.

References

  1. Capricor Therapeutics (2023) press release, December 11, 2023 (opens in a new tab)
  2. Capricor Therapeutics (2025) press release, June 11, 2025 (opens in a new tab)
  3. Capricor Therapeutics (2026) corporate presentation, August 2026 (opens in a new tab)
  4. Capricor Therapeutics (2026) Form 10-K for 2025 (opens in a new tab)
  5. Capricor Therapeutics (2026) press release, October 5, 2026 (opens in a new tab)
  6. Capricor Therapeutics (2026) website, Duchenne Muscular Dystrophy Overview (opens in a new tab)
  7. NS Pharma (2026) website, Duchenne (opens in a new tab)